In the last trading session, 1.86 million Standard BioTools Inc (NASDAQ:LAB) shares changed hands as the company’s beta touched 1.54. With the company’s per share price at $1.29 changed hands at $0.09 or 7.50% during last session, the market valuation stood at $489.97M. LAB’s last price was a discount, traded about -86.82% off its 52-week high of $2.41. The share price had its 52-week low at $0.92, which suggests the last value was 28.68% up since then. When we look at Standard BioTools Inc’s average trading volume, we note the 10-day average is 4.22 million shares, with the 3-month average coming to 1.73 million.
Analysts gave the Standard BioTools Inc (LAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LAB as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
Standard BioTools Inc (NASDAQ:LAB) trade information
Instantly LAB was in green as seen at the end of in last trading. With action 5.74%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -27.12%, with the 5-day performance at 5.74% in the green. However, in the 30-day time frame, Standard BioTools Inc (NASDAQ:LAB) is 27.72% up. Looking at the short shares, we see there were 16.16 million shares sold at short interest cover period of 11.03 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3.25, meaning bulls need an upside of 60.31% from its current market value. According to analyst projections, LAB’s forecast low is 3.25 with 3.25 as the target high. To hit the forecast high, the stock’s price needs a -151.94% plunge from its current level, while the stock would need to soar -151.94% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.61%. The 2025 estimates are for Standard BioTools Inc earnings to increase by 55.47%, but the outlook for the next 5-year period is at 66.44% per year.
LAB Dividends
Standard BioTools Inc is expected to release its next quarterly earnings report on 2025-May-06.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.53% of Standard BioTools Inc shares while 73.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 74.22%. There are 73.09% institutions holding the Standard BioTools Inc stock share, with CASDIN CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 17.1782% of the shares, roughly 63.96 million LAB shares worth $113.21 million.
VIKING GLOBAL INVESTORS LP holds the second largest percentage of outstanding shares, with 15.7524% or 58.65 million shares worth $103.81 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 9.17 shares estimated at $11.83 million under it, the former controlled 2.41% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.89% of the shares, roughly 7.2 shares worth around $9.28 million.
